MedPath

Beclomethasone Dipropionate

Generic Name
Beclomethasone Dipropionate
Brand Names
Alanase, Beconase, Propaderm, Qnasl, Qvar, Rivanase AQ
Drug Type
Small Molecule
Chemical Formula
C28H37ClO7
CAS Number
5534-09-8
Unique Ingredient Identifier
5B307S63B2
Background

Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration. Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. Due to its anti-inflammatory, antipruritic, and anti-allergy properties, beclomethasone dipropionate is used in various inflammatory conditions, such as asthma, allergic rhinitis, and dermatoses to reduce symptoms. When inhaled, it is proposed that beclomethasone dipropionate remains active locally in the lung without causing significant side effects associated with systemic corticosteroids. Compared to earlier corticosteroids such as dexamethasone and prednisolone, beclomethasone dipropionate is reported to be less irritating to the nasal mucosa with a longer duration of action when administered intranasally.

Indication

糖皮质激素类药。主要用于持续性哮喘的长期治疗。按照支气管哮喘严重程度分级标准,在轻度持续(2级以上)即可使用吸入糖皮质激素治疗;外用适用于对糖皮质激素外用有效的各种非感染性炎症性皮肤病,如亚急性和慢性湿疹、脂溢性皮炎、接触性皮炎、特应性皮炎、局限性神经性皮炎、寻常型银屑病、盘状红斑狼疮、扁平苔癣等。亦可用于常年性变应性鼻炎和季节性变应性鼻炎及血管收缩性鼻炎;亦用于鼻息肉切除术后,预防息肉的再生。

Associated Conditions
Asthma, Bacterial Sinusitis, Chronic Sinusitis, Dermatosis, Fungal skin infection, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Recurrent nasal polyps

Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2010-09-17
Last Posted Date
2012-07-03
Lead Sponsor
University Hospital, Antwerp
Target Recruit Count
29
Registration Number
NCT01204034
Locations
🇧🇪

University Hospital of Antwerp, Edegem (Antwerp), Antwerp, Belgium

Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)

Not Applicable
Completed
Conditions
Asthma
Interventions
First Posted Date
2010-06-14
Last Posted Date
2019-04-02
Lead Sponsor
Henry Ford Health System
Target Recruit Count
362
Registration Number
NCT01142947
Locations
🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management

Completed
Conditions
Asthma
Interventions
Drug: Extra-fine hydrofluoroalkane-beclomethasone dipropionate
Drug: Chlorofluorocarbon beclomethasone dipropionate
First Posted Date
2010-06-10
Last Posted Date
2013-03-14
Lead Sponsor
Research in Real-Life Ltd
Target Recruit Count
815377
Registration Number
NCT01141439
Locations
🇬🇧

General Practice Research Database, London, United Kingdom

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

Phase 3
Completed
Conditions
Perennial Allergic Rhinitis
Interventions
Drug: Placebo Nasal Aerosol
Drug: Placebo Prednisone Capsules
First Posted Date
2010-05-31
Last Posted Date
2012-07-04
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
107
Registration Number
NCT01133626
Locations
🇺🇸

Teva Clinical Study Site, San Antonio, Texas, United States

Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone

Phase 3
Completed
Conditions
Asthma
Allergic Rhinitis
Interventions
First Posted Date
2010-04-30
Last Posted Date
2010-07-27
Lead Sponsor
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Target Recruit Count
32
Registration Number
NCT01113489
Locations
🇮🇹

Unit of Immunopathology and Pharmacology of the Respiratory System Institute of Biomedicine and Molecular Immunology (IBIM) Italian National Research (CNR), Palermo, Italy

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

Phase 3
Completed
Conditions
Seasonal Allergic Rhinitis
Hay Fever
Interventions
Drug: Placebo Nasal Aerosol
First Posted Date
2009-12-03
Last Posted Date
2021-12-03
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
340
Registration Number
NCT01024608
Locations
🇺🇸

Teva Clinical Trial Site, Waco, Texas, United States

A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis

Phase 1
Completed
Conditions
Eosinophilic Esophagitis
Interventions
First Posted Date
2009-11-19
Last Posted Date
2012-11-30
Lead Sponsor
Penn State University
Target Recruit Count
20
Registration Number
NCT01016223
Locations
🇺🇸

Penn State Hershey Medical Center, Hershey, Pennsylvania, United States

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

Phase 3
Completed
Conditions
Rhinitis, Allergic, Perennial
Interventions
Drug: Placebo Nasal Aerosol
First Posted Date
2009-10-02
Last Posted Date
2021-12-03
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
529
Registration Number
NCT00988247
Locations
🇺🇸

Teva Clinical Sudy Site, Oxford, Alabama, United States

🇺🇸

Teva Clinical Study Site, West Allis, Wisconsin, United States

Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2009-06-01
Last Posted Date
2013-07-10
Lead Sponsor
Wilfried De Backer
Target Recruit Count
29
Registration Number
NCT00910793
Locations
🇧🇪

University Hospital Antwerp, Antwerp, Belgium

FACTO Study (Foster® As Complete Treatment Option)

Phase 4
Completed
Conditions
Asthmatic Patients
Interventions
First Posted Date
2009-05-13
Last Posted Date
2017-03-30
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
431
Registration Number
NCT00901368
Locations
🇫🇷

Hôpital Nord, Marseille, France

🇳🇱

Atrium Medisch Centrum Heerlen,, Heerlen, Netherlands

🇩🇪

Allergologie imUmkreis der Praxis Pneumologie, Gelsenkirchen, Nordrhein-Westfalen, Germany

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath